For the estimated 800 million people who struggle to follow a conversation in a crowded room, the problem is not in the ear. It is in the brain. This condition, known as central hearing loss or cocktail party syndrome, stems from age-related damage to the myelin sheaths insulating neural circuits in the auditory brainstem. Hearing aids, which amplify sound, do little to help. The standard of care, for decades, has been to offer no care at all [CU Anschutz News, 2025].
Parley Neurotech, a 2025 spinout from the University of Colorado Anschutz Medical Campus, is now enrolling its first patients in a Phase 2 clinical trial for what could become the first treatment for this neural deficit. Its approach, called Localized Oligodendrocyte Optimization Therapy (LOOT), is a non-invasive device that combines a proprietary engineered sound therapy with an already FDA-approved drug, aiming to stimulate the repair of damaged myelin and restore the brain's ability to filter speech from noise [CU Anschutz News, 2025].
The science behind the spinout
The company's foundation is a specific biological discovery published in a 2024 preprint. Research from the Klug Lab at CU Anschutz demonstrated that age-related myelin deficits in the auditory brain stem are a primary contributor to cocktail-party hearing deficits, implicating impaired oligodendrocyte maturation [bioRxiv, 2024]. This work provided a clear cellular target: the oligodendrocytes that produce and maintain myelin. The LOOT therapy is designed to directly address this, using a precisely engineered auditory stimulus to activate these cells in conjunction with a drug that promotes myelination [CU Anschutz News, 2025].
The founding team is a direct translation of that lab work. Achim Klug, the PhD who led the discovery, serves as Chief Scientific Officer. His co-founder and CEO, Sam Budoff, is a computational neuroscientist who joined the Klug Lab after a stint as an early employee at biofabrication startup Modern Meadow. Budoff's PhD work mapped spatial properties of retinal cells, a skillset he applies to the spatial hearing problem [Klug Lab, 2026]. The company's initial backing comes not from venture capital, but from the academic and grant ecosystem that nurtured the science.
| Founder | Role | Key Background |
|---|---|---|
| Sam Budoff, PhD | CEO | Computational neuroscientist, former early employee at Modern Meadow, PhD from CU Anschutz [Klug Lab, 2026]. |
| Achim Klug, PhD | CSO | Principal investigator of the Klug Lab, discoverer of the myelin-deficit cause of central hearing loss, NIH R01 grant PI [CU Anschutz News, 2025]. |
A path defined by regulatory milestones
For a therapeutic device, progress is measured in clinical phases, not monthly active users. Parley's most significant milestone to date is its FDA Phase 2 approval, granted in 2025 with first patient enrollment planned for October of that year [CU Anschutz News, 2025]. This places the company on a defined, if long, regulatory pathway. The therapy's use of an already-approved drug could streamline safety reviews, though its novel combination and delivery mechanism will still require rigorous validation.
The company's early support reflects its academic origins. Its listed investors are SPARK CU Innovations, the university's commercialization engine, and an NIH R01 grant held by Klug and collaborator Dan Tollin [F6S, 2025]. This funding profile underscores a high-risk, research-intensive endeavor still in the translational valley between lab discovery and commercial product.
The risks on the road to clinic
The ambition is clear, but the road from Phase 2 to a commercial treatment is famously fraught. Parley Neurotech's journey will be defined by a series of concrete, binary hurdles.
- Clinical data. The company cites ~90% preclinical reversal of cocktail party deficits in animal models [Healthy Team Podcast, 2025]. That striking figure remains unpublished and must now be proven safe and effective in humans across two more clinical trial phases. The difference between rodent brainstem physiology and a 65-year-old human's is vast.
- Commercial runway. With no disclosed venture funding, the company's financial capacity to navigate years of costly trials is unclear. An NIH grant and university support provide a start, but Phase 3 trials typically require orders of magnitude more capital.
- Market education. The company must define and educate a market for a condition most people and many physicians do not know has a name, let alone a potential treatment. This is a foundational marketing challenge atop the scientific one.
Success would not mean competing with hearing aid giants like Sonova or Demant, but creating an entirely new therapeutic category adjacent to them. The patient population is undeniably large, but the company must first prove its device works, then convince a fragmented healthcare system to pay for it.
For the target patient, the standard of care today is a study in frustration. An individual with normal hearing thresholds might pass a standard audiogram yet consistently miss words in a noisy restaurant or family gathering. They are often told their hearing is "fine," or are fitted with hearing aids that amplify both speech and noise, offering little relief. The result is social withdrawal, cognitive strain, and a lack of medical options. Parley Neurotech's bet is that the solution lies not in the ear canal, but in a non-invasive protocol to repair the insulation on the brain's own wiring. The Phase 2 trial results, when they come, will show if that bet has a sound basis.
Sources
- [CU Anschutz News, 2025] A First-of-its-kind Treatment for Brain-Based Hearing Loss | https://news.cuanschutz.edu/cu-innovations/first-of-its-kind-treatment-for-brain-based-hearing-loss
- [F6S, 2025] Parley Neurotech | F6S | https://www.f6s.com/company/parley-neurotech
- [bioRxiv, 2024] Age-related myelin deficits in the auditory brain stem contribute to cocktail-party deficits | https://www.biorxiv.org/content/10.1101/2024.07.29.605710v1.full
- [Klug Lab, 2026] Welcoming Dr. Sam Budoff: Bridging Spatial Vision and Spatial Hearing | https://www.kluglab.org/hearing-loss-blog/welcoming-dr-sam-budoff-bridging-spatial-vision-and-spatial-hearing
- [Healthy Team Podcast, 2025] Healthy Team Podcast with guests Sam Budoff, CEO and Achim Klug (Audible) | Source referenced for preclinical data claim.